Reproductive and Lifestyle Factors and Circulating sRANKL and OPG Concentrations in Women: Results from the EPIC Cohort

Background: Except for a documented increase in osteoprotegerin (OPG) concentrations with older age, data on determinants of soluble Receptor Activator of Nuclear Factor κB (sRANKL) and OPG concentrations in women are limited. We evaluated reproductive and lifestyle factors as potential sources of variation in circulating sRANKL and OPG concentrations in pre- and postmenopausal women. Methods: This study includes 2,016 controls [n = 1,552 (76%) postmenopausal, n = 757 (38%) using postmenopausal hormone therapy (PMH)] from a breast cancer case–control study nested in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Serum sRANKL was measured using an ELISA and serum OPG using an electrochemiluminescent assay. Generalized linear models were used to evaluate associations between these analytes and reproductive and lifestyle factors. Results: Older age at blood collection was associated with lower sRANKL concentrations in postmenopausal women (Ptrend ≤ 0.03) and higher OPG concentrations in all women (Ptrend ≤ 0.01). Longer duration of oral contraceptive use among premenopausal women and postmenopausal PMH users was associated with higher OPG (Ptrend ≤ 0.04). In postmenopausal non-PMH users, sRANKL concentrations were lower with longer duration of oral contraceptive use and current (vs. never) smoking (P ≤ 0.01). sRANKL concentrations were higher among women with higher BMI (Ptrend ≤ 0.01). The evaluated factors accounted for 12% of the variation in sRANKL concentrations and 21% of the variation in OPG concentrations. Conclusions: Circulating sRANKL and OPG concentrations are minimally impacted by hormone-related factors in pre- and postmenopausal women. Impact: This study suggests circulating concentrations of sRANKL and OPG are unlikely to be strongly modified by hormone-related reproductive and lifestyle factors.

[1]  R. Kimmig,et al.  Prognostic Value of RANKL/OPG Serum Levels and Disseminated Tumor Cells in Nonmetastatic Breast Cancer , 2018, Clinical Cancer Research.

[2]  J. Chang-Claude,et al.  Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort , 2018, BMC Cancer.

[3]  E. Riboli,et al.  Circulating RANKL and RANKL/OPG and Breast Cancer Risk by ER and PR Subtype: Results from the EPIC Cohort , 2017, Cancer Prevention Research.

[4]  E. Riboli,et al.  Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort , 2017, BMC Medicine.

[5]  G. Bozkaya,et al.  Comparison the relationship between the levels of insulin resistance, hs-CRP, percentage of body fat and serum osteoprotegerin/receptor activator of nuclear factor κβ ligand in prediabetic patients. , 2017 .

[6]  G. Carpenter,et al.  Impact of Obesity on Orthodontic Tooth Movement in Adolescents: A Prospective Clinical Cohort Study , 2017, Journal of dental research.

[7]  A. Teschendorff,et al.  Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer , 2016, Oncotarget.

[8]  L. Salmena,et al.  Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers , 2016, Oncotarget.

[9]  E. González-Suárez,et al.  RANK as a therapeutic target in cancer , 2016, The FEBS journal.

[10]  L. Kiesel,et al.  Role of the RANK/RANKL pathway in breast cancer. , 2016, Maturitas.

[11]  I. Jacobs,et al.  Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers , 2015, EBioMedicine.

[12]  J. Hansen,et al.  Serum osteoprotegerin and future risk of cancer and cancer-related mortality in the general population: the Tromsø study , 2015, European Journal of Epidemiology.

[13]  R. Kovatcheva,et al.  Age and Menopausal Status Affect Osteoprotegerin and Osteocalcin Levels in Women Differently, Irrespective of Thyroid Function , 2014, Clinical medicine insights. Endocrinology and diabetes.

[14]  D. Findlay,et al.  Relationship between serum RANKL and RANKL in bone , 2011, Osteoporosis International.

[15]  A. Trouvin,et al.  Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss , 2010, Clinical interventions in aging.

[16]  J. Visvader,et al.  Control of mammary stem cell function by steroid hormone signalling , 2010, Nature.

[17]  B. Larijani,et al.  Relationships among serum receptor of nuclear factor-&kgr;B ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineraldensity in postmenopausal women: osteoimmunity versus osteoinflammatory , 2009, Menopause.

[18]  D. Edwards,et al.  Transcriptional response of the murine mammary gland to acute progesterone exposure. , 2008, Endocrinology.

[19]  Bruce K Armstrong,et al.  International Journal of Behavioral Nutrition and Physical Activity Validity and Repeatability of the Epic Physical Activity Questionnaire: a Validation Study Using Accelerometers as an Objective Measure , 2007 .

[20]  D. Kiel,et al.  Increased plasma osteoprotegerin concentrations are associated with indices of bone strength of the hip. , 2008, The Journal of clinical endocrinology and metabolism.

[21]  S. Khalifé,et al.  Osteoprotegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals: results from both cross-sectional and interventional study. , 2008, European journal of endocrinology.

[22]  K. Arisawa,et al.  Circulating profiles of osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in post-menopausal women , 2008, Journal of endocrinological investigation.

[23]  Brendan F Boyce,et al.  Biology of RANK, RANKL, and osteoprotegerin , 2007, Arthritis research & therapy.

[24]  M. Losa,et al.  Growth hormone stimulates osteoprotegerin expression and secretion in human osteoblast-like cells. , 2007, The Journal of endocrinology.

[25]  Amanda L. Johnson,et al.  Effects of hyaluronan treatment on lipopolysaccharide-challenged fibroblast-like synovial cells , 2007, Arthritis research & therapy.

[26]  C. Friedenreich,et al.  Physical Activity and Risk of Colon and Rectal Cancers: The European Prospective Investigation into Cancer and Nutrition , 2006, Cancer Epidemiology Biomarkers & Prevention.

[27]  G. Paolisso,et al.  Increased serum osteoprotegerin values in long-lived subjects: different effects of inflammation and bone metabolism. , 2006, European journal of endocrinology.

[28]  J. Chang-Claude,et al.  Serum Sex Steroids in Premenopausal Women and Breast Cancer Risk Within the European Prospective Investigation into Cancer and Nutrition (EPIC) , 2005 .

[29]  P. Kostenuik,et al.  Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins. , 2005, Bone.

[30]  S. Théoleyre,et al.  The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. , 2004, Cytokine & growth factor reviews.

[31]  Qingbo Xu,et al.  Soluble RANKL and risk of nontraumatic fracture. , 2004, JAMA.

[32]  L. Hofbauer,et al.  Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women , 2004, Clinical endocrinology.

[33]  W. Fraser,et al.  Effect of anticoagulants and storage temperature on the stability of receptor activator for nuclear factor-kappa B ligand and osteoprotegerin in plasma and serum. , 2003, Clinical chemistry.

[34]  R. Kitazawa,et al.  Receptor activator of NF-kappaB ligand induction via Jak2 and Stat5a in mammary epithelial cells. , 2003, The Journal of biological chemistry.

[35]  P. Pietschmann,et al.  Serum levels of osteoprotegerin increase with age in a healthy adult population. , 2003, Bone.

[36]  N E Day,et al.  European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection , 2002, Public Health Nutrition.

[37]  E. Liao,et al.  Comparison of the effects of 17β-E2 and progesterone on the expression of osteoprotegerin in normal human osteoblast-like cells , 2002 .

[38]  L. Melton,et al.  Correlates of Osteoprotegerin Levels in Women and Men , 2002, Osteoporosis International.

[39]  William Maloney,et al.  Receptor Activator of NF-κB and Osteoprotegerin Expression by Human Microvascular Endothelial Cells, Regulation by Inflammatory Cytokines, and Role in Human Osteoclastogenesis* , 2001, The Journal of Biological Chemistry.

[40]  D. Lacey,et al.  The Osteoclast Differentiation Factor Osteoprotegerin-Ligand Is Essential for Mammary Gland Development , 2000, Cell.

[41]  D. Lacey,et al.  Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. , 1999, Endocrinology.

[42]  B. Rosner.  Percentage Points for a Generalized ESD Many-Outlier Procedure , 1983 .

[43]  G. Bozkaya,et al.  Relationship between insulin resistance, hs-CRP, and body fat and serum osteoprotegerin/RANKL in prediabetic patients. , 2017, Minerva endocrinologica.

[44]  Teiji Wada,et al.  RANKL-RANK signaling in osteoclastogenesis and bone disease. , 2006, Trends in molecular medicine.

[45]  J. Chang-Claude,et al.  Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). , 2005, Journal of the National Cancer Institute.

[46]  L. Sun,et al.  Relationships Between the Changes of Serum Levels of OPG and RANKL with Age, Menopause, Bone Biochemical Markers and Bone Mineral Density in Chinese Women Aged 20-75 , 2004, Calcified Tissue International.

[47]  J. Visvader,et al.  Investigation of the transcriptional changes underlying functional defects in the mammary glands of prolactin receptor knockout mice. , 2003, Recent progress in hormone research.

[48]  E. Liao,et al.  Comparison of the effects of 17beta-E2 and progesterone on the expression of osteoprotegerin in normal human osteoblast-like cells. , 2002, Journal of endocrinological investigation.

[49]  J. Penninger,et al.  RANK-L and RANK: T cells, bone loss, and mammalian evolution. , 2002, Annual review of immunology.

[50]  S. Kido,et al.  17beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha. , 2001, Endocrinology.